Late-stage study of Mesoblast cell therapy in COVID-19 excel 50% enrollment

Mesoblast Limited (NASDAQ:MESO) +2% premarket says that the randomized controlled Phase 3 trial of remestemcel-L, an allogeneic mesenchymal stem cell product derived from bone marrow, in COVID-19 pat… [read more]

Leave a Comment